Catheter ablation is an established method for treating supraventricular and ventricular arrhythmias. Patients with atrial fibrillation should also use anticoagulant therapy to prevent thromboembolic events, even during ablation. The number of patients being treated with new anticoagulants (NOACs) is increasing, but the use of direct factor Xa inhibitors poses a risk of life-threatening bleeding during catheterization if a specific antidote is not available at the healthcare facility. Options to prevent this complication include short-term switching to dabigatran or complete interruption of NOACs therapy with temporary heparin support. The aim of the presented study was to compare the safety and feasibility of both methods.

At the XXVIIIth Pařízek Days held in Ostrava, a case of acquired hemophilia A, recently addressed at this institution, was presented in the afternoon session on March 17, 2022, by Assoc. Prof. Petr Dulíček, MD, PhD., from the 4th Department of Internal Medicine, Charles University Faculty of Medicine and University Hospital in Hradec Králové.

Modern antidiabetics –⁠ gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) –⁠ significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio -⁠ and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been shown by the prospective randomized EMPA-REG OUTCOME study and the real-world EMPRISE evaluation.

The American Society of Hematology (ASH) guidelines from 2019 highlighted several important aspects in the diagnosis and treatment of ITP that have remained unchanged from the 2011 guidelines.

The incidence of type 2 diabetes mellitus (DM2) and cardiovascular diseases (CVD) is strongly influenced by lifestyle and diet. Hypertension, hypercholesterolemia, and elevated blood glucose are often detectable before the full development of disease symptoms. Similarly, changes in the representation of other less noticeable markers—plasma lipids—can also be detected.

High-resolution computed tomography (HRCT) imaging of the lungs is a fundamental examination in diagnosing idiopathic pulmonary fibrosis (IPF). According to experts from the Mayo Clinic, it can also serve as a tool for more accurate prediction of survival time in IPF patients.

The goal of glaucoma treatment is to preserve the visual field and the quality of life of patients. Currently, the only approach to preserving the visual field of patients is to reduce intraocular pressure (IOP). Its target value should be determined for each patient with consideration of individual risk factors. The following comprehensive infographic shows which factors should be considered according to the current recommendations of the European Glaucoma Society (EGS).

Treatment of older patients and those with chronic lymphocytic leukemia (CLL) who are not in good physical condition has advanced significantly in recent years. The addition of obinutuzumab to chlorambucil therapy has extended both progression-free survival and overall survival for patients. The authors of the presented study evaluated the efficacy and safety of obinutuzumab in real-world clinical practice.

Diosmin and hesperidin belong to the group of bioflavonoids, which currently find wide application in the treatment of chronic venous insufficiency and hemorrhoidal disease. Both flavonoids have been described to have a similar, but still not fully understood mechanism of action. Nevertheless, diosmin significantly differs from hesperidin, especially in pharmacokinetic parameters, which makes it the main carrier of the effect of venotonics.

At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and June in Milan, Italy, a study was presented that examined the impact of tofacitinib use on cardiovascular (CV) risk in patients with active rheumatoid arthritis (RA).

There is growing evidence of the cardiorenal protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), which were developed as antihyperglycemic drugs for the treatment of type 2 diabetes. These antidiabetic medications are recommended for patients with heart or renal disease or at high risk of these complications. However, is it worthwhile to consider their use in diabetics as part of long-term primary cardiorenal prevention? Israeli authors sought the answer to this question.

Dental prostheses are one of the most common solutions for missing teeth, especially in the elderly population. It is estimated that by 2050 up to 2 billion people will be aged 60 or older. Currently, it's not even half that, so it's likely that the number of people with dental prostheses will continue to increase. What do current research findings on dental prosthesis care reveal, and which cleaning methods have been evaluated as truly effective?

The randomized phase III study QUAZAR AML-001 evaluated the maintenance treatment of acute myeloid leukemia (AML) in patients after first remission. The following text summarizes the findings regarding the most common adverse events (AEs) in this therapy and practical recommendations for managing side effects based on guidelines from professional societies.

In recent years, there have been significant advances in the diagnosis and therapy of acute myeloid leukemia (AML). High-quality laboratory diagnostics (molecular genetics, cytogenetics, and flow cytometry) are absolutely essential, and monitoring measurable residual disease is becoming increasingly important. The range of treatment options is also beginning to expand. The content of the latest 'Recommendations for the Diagnosis and Treatment of Acute Myeloid Leukemia (AML),' which are part of this year's updated 'Red Book' of the Czech Hematology Society ČLS JEP (CHS), is primarily based on the 2022 European Leukemia Network (ELN) guidelines and offers, among other things, an updated disease classification and risk stratification, as well as an overview of current treatment options for both intensive and non-intensive regimens.

In June 2020, the journal Radiology and Oncology published the results of an analysis of data from patients with stage III non-small-cell lung cancer (NSCLC) from a Central European registry. A large team led by Czech experts focused on the diagnostic and therapeutic procedures used and the treatment results achieved in real-world practice.